Patents

US 11786516 B2: Methods of treating Fabry patients having renal impairment

Granted
2023-10-17
Filed
2022-12-21 application 18069720
Type
Utility · 19 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in α-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.

Source: PVGPATDIS, file of 2026-04-10 (ipg231017.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
Amicus Therapeutics, Inc. 158 patentsUS company or organizationPhiladelphia, PAAMICUS THERAPEUTICS, INC. Form D issuer EXACT high confidence: identical full name and state
AMICUS THERAPEUTICS, INC. SEC filer EXACT medium confidence: identical full name, one of each nationally
PVGPATDIS, file of 2026-04-10

Inventors

InventorPlacePatentsPerson pageSource
Jeff CastelliNew Hope, PA59PVGPATDIS, file of 2026-04-10
Elfrida BenjaminMillstone Township, NJ57PVGPATDIS, file of 2026-04-10

CPC categories

SubclassCategoryFirst groupSource
A61KPreparations for medical, dental or toiletry purposesA61K31/445PVGPATDIS, file of 2026-04-10
A61PSpecific therapeutic activity of chemical compounds or medicinal preparationsA61P13/12PVGPATDIS, file of 2026-04-10

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

RecordedWhatFromToReel/frameSource
2026-04-27Release of security interest
Release of security interest
WILMINGTON TRUST, NATIONAL ASSOCIATION signed 2026-04-27AMICUS THERAPEUTICS, INC. PHILADELPHIA, PA75494/30PASDL, file of 2026-08-13
2026-04-27Security interest Security interest
Security interest
BIOMARIN PHARMACEUTICAL INC. signed 2026-04-27
AMICUS THERAPEUTICS, INC. signed 2026-04-27
CITIBANK, N.A., AS COLLATERAL AGENT NEW YORK, NY75493/968PASDL, file of 2026-10-15
2023-10-06Security interest Security interest
Security interest
AMICUS THERAPEUTICS, INC. signed 2023-10-05WILMINGTON TRUST, NATIONAL ASSOCIATION MINNEAPOLIS, MN65177/196PASDL, file of 2026-10-15

Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.